Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory circuits During Response to MAPK Inhibition in BRAF-mutant colorectal cancer
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 36 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Colorectal cancerThis series is part of our curated briefing on it.
- Samples
- 36 samples: 36 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE280280_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1177515 and SRA study SRP540717. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 36 sample titles: 36 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8593952 C5002; combo 2; BRD2; ChIP
- GSM8593953 C5002; combo 2; BRD4; ChIP
- GSM8593954 C5002; combo 2; Input; ChIP
- GSM8593955 C5002; combo 3; BRD2; ChIP
- GSM8593956 C5002; combo 3; BRD4; ChIP
- GSM8593957 C5002; combo 3; Input; ChIP
- GSM8593958 C5002; control 1; BRD2; ChIP
- GSM8593959 C5002; control 1; BRD4; ChIP
- GSM8593960 C5002; control 1; Input; ChIP
- GSM8593961 C5002; control 2; BRD2; ChIP
- GSM8593962 C5002; control 2; BRD4; ChIP
- GSM8593963 C5002; control 2; Input; ChIP
- GSM8593964 C5002; control 3; BRD2; ChIP
- GSM8593965 C5002; control 3; BRD4; ChIP
- GSM8593966 C5002; control 3; Input; ChIP
- GSM8593967 C5002; encorafenib+cetuximab 1; BRD2; ChIP
- GSM8593968 C5002; encorafenib+cetuximab 1; BRD4; ChIP
- GSM8593969 C5002; encorafenib+cetuximab 1; Input; ChIP
- GSM8593970 C5002; encorafenib+cetuximab 2; BRD2; ChIP
- GSM8593971 C5002; encorafenib+cetuximab 2; BRD4; ChIP
- GSM8593972 C5002; encorafenib+cetuximab 2; Input; ChIP
- GSM8593973 C5002; encorafenib+cetuximab 3; BRD2; ChIP
- GSM8593974 C5002; encorafenib+cetuximab 4; BRD4; ChIP
- GSM8593975 C5002; encorafenib+cetuximab 5; Input; ChIP
- GSM8593976 C5002; zen3694 1; BRD2; ChIP
- GSM8593977 C5002; zen3694 1; BRD4; ChIP
- GSM8593978 C5002; zen3694 1; Input; ChIP
- GSM8593979 C5002; zen3694 2; BRD2; ChIP
- GSM8593980 C5002; zen3694 2; BRD4; ChIP
- GSM8593981 C5002; zen3694 2; Input; ChIP
- GSM8593982 C5002; zen3694 3; BRD2; ChIP
- GSM8593983 C5002; zen3694 3; BRD4; ChIP
- GSM8593984 C5002; zen3694 3; Input; ChIP
- GSM8593985 C5002; combo 1; BRD2; ChIP
- GSM8593986 C5002; combo 1; BRD4; ChIP
- GSM8593987 C5002; combo 1; Input; ChIP
- GSE12032 Inherent gene signature of stage II and III colorectal cancer leads in individual recurrence 198 samples same disease briefing
- GSE109308 Single-cell transcriptomic survey of adenomatous polyposis patients with germline APC mutations 97 samples same disease briefing
- GSE110009 Single cell transcriptome landscape of primary and metastatic tumor in colon cancer 76 samples same disease briefing
- GSE250000 Bulk RNA-sequencing of transduced colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 overexpressing full-lenght p53β or p53β-stop-lost. 4 samples same disease briefing
- GSE309034 Combined BET Bromodomain and DNMT Inhibition Targets Lineage Plasticity in Prostate Cancer [BETi_DNMTi_human_RNAseq] 44 samples shares ets, plasticity, inhibition
- GSE303106 Prolonged KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals Therapeutic Opportunities [cut and run-ChipSeq] 9 samples shares mapk, inhibition
- GSE248208 Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition 99 samples shares mapk, inhibition
- GSE303051 Prolonged KRAS-MAPK Inhibition Induces Interferon-mediated Epithelial-to-Mesenchymal Transition and Reveals Therapeutic Opportunities. 30 samples shares mapk, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.